intepirdine   Click here for help

GtoPdb Ligand ID: 9444

Synonyms: RVT-101 | SB-742457
Compound class: Synthetic organic
Comment: Intepirdine (RVT-101) is a 5-HT6 receptor antagonist [4] (called SB-742457 in this article). Developed by Axovant Science Ltd.
Phase 3 clinical trial results for RVT-101 are eagerly awaited given the reported failures of competitors' 5-HT6 receptor antagonists in Alzheimer's disease trials (e.g. Lundbeck's idalopirdine, and Pfizer's PF-05212377).
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

intepirdine is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 70.68
Molecular weight 353.12
XLogP 2.83
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES O=S(=O)(c1cnc2c(c1)cccc2N1CCNCC1)c1ccccc1
Isomeric SMILES O=S(=O)(c1cnc2c(c1)cccc2N1CCNCC1)c1ccccc1
InChI InChI=1S/C19H19N3O2S/c23-25(24,16-6-2-1-3-7-16)17-13-15-5-4-8-18(19(15)21-14-17)22-11-9-20-10-12-22/h1-8,13-14,20H,9-12H2
InChI Key JJZFWROHYSMCMU-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Callaghan CK, Hok V, Della-Chiesa A, Virley DJ, Upton N, O'Mara SM. (2012)
Age-related declines in delayed non-match-to-sample performance (DNMS) are reversed by the novel 5HT6 receptor antagonist SB742457.
Neuropharmacology, 63 (5): 890-7. [PMID:22766392]
2. Ferrero H, Solas M, Francis PT, Ramirez MJ. (2017)
Serotonin 5-HT6 Receptor Antagonists in Alzheimer's Disease: Therapeutic Rationale and Current Development Status.
CNS Drugs, 31 (1): 19-32. [PMID:27914038]
3. Krogsgaard-Larsen N, Jensen AA, Schrøder TJ, Christoffersen CT, Kehler J. (2014)
Novel aza-analogous ergoline derived scaffolds as potent serotonin 5-HT₆ and dopamine D₂ receptor ligands.
J Med Chem, 57 (13): 5823-8. [PMID:24878269]
4. Liu KG, Lo JR, Comery TA, Zhang GM, Zhang JY, Kowal DM, Smith DL, Di L, Kerns EH, Schechter LE et al.. (2009)
Identification of a novel series of 3-piperidinyl-5-sulfonylindazoles as potent 5-HT6 ligands.
Bioorg Med Chem Lett, 19 (12): 3214-6. [PMID:19433358]
5. Maher-Edwards G, Dixon R, Hunter J, Gold M, Hopton G, Jacobs G, Hunter J, Williams P. (2011)
SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study.
Int J Geriatr Psychiatry, 26 (5): 536-44. [PMID:20872778]
6. Maher-Edwards G, Zvartau-Hind M, Hunter AJ, Gold M, Hopton G, Jacobs G, Davy M, Williams P. (2010)
Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease.
Curr Alzheimer Res, 7 (5): 374-85. [PMID:20043816]
7. Rossé G, Schaffhauser H. (2010)
5-HT6 receptor antagonists as potential therapeutics for cognitive impairment.
Curr Top Med Chem, 10 (2): 207-21. [PMID:20166958]